Piper Sandler analyst Allison Bratzel downgraded Inozyme (INZY) to Neutral from Overweight with a $4 price target after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme downgraded to Hold from Buy at Jefferies
- Leerink bullish on BioMarin following Inozyme deal, expects additional BD
- Inozyme downgraded to Market Perform from Outperform at Raymond James
- Inozyme downgraded to Hold from Buy at Needham
- Inozyme downgraded to Equal Weight from Overweight at Wells Fargo